Upload
anis-wade
View
214
Download
1
Embed Size (px)
Citation preview
Artemisinin- an innovative cornerstone for anti-
malaria therapy
성균관대학교 약학대학천연물약품화학연구실석박통합 7 기 김충섭
About malaria
Market development through supply chain en-largement of A. annua
Ⅰ
III
Contents
From Artemisia annua to artemisinin and Coartem®Ⅱ
Market development through supply chain en-largement of artemisininⅣ
About malariaⅠ
1. Symptoms & Infections
2. Epidemiology & Economic ef-
fects
3. Research
4. Prevention
5. Treatment
센터의 필요성 Ⅰ. About malariaAbout malaria
Malaria
Symptoms- Flu-like symptoms- High-fever, intermittent fever- Coma, death Infections- Blood parasite Plasmod-ium- Anopheles mosquitoes
Epidemiology- Often in Africa- 500 million infection/year- 1 children/30 sec dies
Economic effects- USD 12 billion/year- No economic develop-ment- No tourism
Research- About infection cy-cle and vector control- Four Nobel prizes (1902, 04, 27, 48)
Prevention- Insecticide-treated bed nets- Indoor Residual Spray-ing- Treat mosquitoes’ breeding areas with insecticides
Treatment- Artemisinin-based Combination Therapies (ACT)
- ‘Roll Back Malaria’ (RBM) by WHO, IRBD, UNDP, and UNICEF
- Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)
From Artemisia annua to artemisinin and Coartem®
1. Antimalarial activity of Qinghao (A.
annua L.)
2. Artemisinin from A. annua L.
3. Congeners of artemisinin
4. Development of ACT – Coartem®
Ⅱ
Ⅱ. From Artemisia annua to
artemisinin and Coartem1. Antimalarial activity of Qinghao (A. annua L.)
(1950s)Drug resis-
tanceto chloro-
quine
(1960s)Malariaout of control
(Vietnam War)Soldiers in-
fected
(1970s)40,000 com-
pounds and ex-tracts screened
in China
Drug resis-tance
Screening Qinghao (Artemisia annua L., 개똥쑥 )
Hemorrhoids(168 BC)
Intermittentfever
(1596 AD)
Fever(300s AD)
Remedies
forQinghao (Yin)
+Internal heat
(Yang)
Sulphadox-ine-
pyrimethamine,
Mefloquine developed
Artemisinin
Arteannuin
Qinghaosu
Ⅱ. From Artemisia annua to
artemisinin and Coartem2. Artemisinin from A. annua L.
Amounts- ↑Leaves, small green stems,
buds, flowers and seeds
- ↓Stems, roots
Sesquiter-penes
Artemisia annua L.
Structure elucidation- NMR, MS and IR
- Sesquiterpene lactone
- C15H22O5
- X-ray crystallography
- 1,2,4-trioxane ring (activity)
Essential oils
Clinical trials- Parasite decreased 95% in 16h
(chloroquine: 40h)
- Effective in resistant spp. and
cerebral form
Ⅱ. From Artemisia annua to
artemisinin and Coartem2. Artemisinin from A. annua L.
SERCA: sarco-endoplasmic reticulum Ca2+-ATPase
Nat. Chem. Biol. 3, 408-414 (2007)
(from hemoglobin)
3. Congeners of artemisinin
Total syntheses- First reported in 1983- Not commercially viable
Characteristics- Thermally stable (~150℃)- Poorly soluble in water and oil- Peroxide: essential for ac-tivity
Dihy-
droartemisinin- More potent- Solubility in water ↓- Stability ↓
Artemether- Soluble in oil- Available by I.M.- Short t1/2
Arteether- Soluble in oil- Available by I.M.
Sodium arte-
sunate- Soluble in wa-ter- Available by I.V.- Short t1/2
OZ277(RBx11160)
- More potent- Long lasting- Structurally simple- Scale-up- Reach market in 2009 (with piperaquine)
Ⅱ. From Artemisia annua to
artemisinin and Coartem®
3. Congeners of artemisinin
Total syntheses- First reported in 1983- Not commercially viable
Characteristics- Thermally stable (~150℃)- Poorly soluble in water and oil- Peroxide: essential for ac-tivity
OZ277(RBx11160)
- More potent- Long lasting- Structurally simple- Scale-up- Reach market in 2009 (with piperaquine)
Artemether- Soluble in oil- Available by I.M.- Short t1/2
Sodium arte-
sunate- Soluble in wa-ter- Available by I.V.- Short t1/2
- Approved as new malarial drugs in China (1986-1987)
- Added to Essential Medicines List(1997, 2000)
Ⅱ. From Artemisia annua to
artemisinin and Coartem®
Ⅱ. From Artemisia annua to
artemisinin and Coartem®4. Development of ACT – Coartem®
Drug resistance to available
agents
Combination therapy- Successful cure rates in
other cases
Combination in antimalaria therapy- Chlorproguanil-dapsone (LapDap)- Dihydroartemisinin/piperaquine (DHA/PPQ)- Artesunate-amodiaquine (AS-AQ)- Artesunate-mefloquine (AS-S/P)- Artesunate/ayronaridine (AS/PRN)
Coartem® (Artemether/lume-fantrine)
Artemether Lume-fantrine
- Only pre-qualified & fixed dose ACT- Cure rates 95 %- Effective on multidrug resis-tance- Registered in 81 countries- 100 million treatments
Market development through supply chain enlargement of A. annua
1. Major challenge in establishing
a supply chain
2. Market situation for A. Annua
3. Plantation efforts to meet market
demands
4. Geographical split of the supply
market
5. Efforts to improve A. annua
biomass
Ⅲ
Ⅲ. Market development through supply chain enlargement of A. annua1. Major challenge in establishing a supply chain
Market develop-ment
• Time needed for season
- Planting
- Cultivating
- Harvesting
Major challenge
• Weather conditions
- Meteorological impacts
• Damage by insects
• Supply and demand
- Oversupply → price ↓
→ business less attractive
→ production reduced
Ⅲ. Market development through supply chain enlargement of A. annua2. Market situation for A. annua
In 2004Unexpected demand for artemisinin
In 2001 Coartem®
launched
Until 2003Sufficient
amounts of A. annua
Whole sup-ply chain
had to built up
Market complexity↑- Harvest earlier → artemisinin content↓- Unsuitable storage → loss of biomass- Extraction, purification x → poor quality
• African countries needed ACTs• Exceed supply capac-ity
Ⅲ. Market development through supply chain enlargement of A. annua3. Plantation efforts to meet market demands
Year
Coartem
Artemisinin required
[kg]
Artemisinin planned for
[kg]
Amount of
biomass [kg]
Required area
[hectares]
Re-marks
2003
1.3 750 750 147,000 53 oversupply
2004
4.4 2,500 2,500 496,000 180 oversupply
2005
30 17,000 17,000 3,382,000 1,230 Max. mar-ket could
supply
2006
120 68,000 124,000 25,000,000 9,000
2007
200 113,000 150,000 30,100,000 11,000
2008
200 113,000 150,000 30,100,000 11,000
Table 1. Demand planning for A. annua and artemisinin in 2004
Local governments
Communities
Mutual agreement
Farmers
Planning – hardly possible- How many kg of biomass may be har-
vested per hectare?
- What would be the artemisinin content
achieved with high yield seeds on larger
plantations?
- No experience of how the huge volumes of
biomass may be dried and processed
Ⅲ. Market development through supply chain enlargement of A. annua3. Plantation efforts to meet market demands
Farmers
Novartis
Extrac-tion company
Communities
Contract
Timely delivery
SeedsSeminars
Economic effects
Biomass man-agers
Meet market de-mands
Ⅲ. Market development through supply chain enlargement of A. annua4. Geographical split of the supply market
Novartis
중국
베트남- Tanzania, Kenya, Uganda- Long experience with culti-vation- Larger areas up to 200 hectares were planted- Irrigation on a large scale
동아프리카
Reduced agricul-
tural risks
Ⅲ. Market development through supply chain enlargement of A. annua5. Efforts to improve A. annua biomass
High yield seeds(being investi-
gated)
Artemisinin content ↑
Planta-tion area
↓
Drying efforts ↓
Trans-port-ation
Storage
Reduced time & cost
Market development through supply chain enlargement of artemisinin
1. Capacity for extraction and
purification: in 2003
2. Major side products (Waxes)
3. Other side products
4. Extraction and purification
2004 onwards
Ⅳ
1. Capacity for extraction and purification: in 2003Ⅳ. Market development through supply chain enlargement of artemisinin
Dried leaves
Hexane or Petroleum ether
Reflux several times
Lipophilic sub-stances (waxes)
EtOAc
Charcoal&
recrystallization
Artemisinin
Solvent – recoveredSilica gel – partially regenerateWithout automation
2. Major side products (Waxes)Ⅳ. Market development through supply chain enlargement of artemisinin
Waxes
- Mixture of long-chain apolar lipids
- Form a protec-tive coating on plant leaves and fruits
- In animals, al-gae, fungi and bacteria
- Not chemically homogeneous group
- Water-resistant
- In crude artemisinin: aliphatic alcohols and hydrocarbons
Identification
- Microscope: difference between the samples with or without waxes can be observed
- IR spectroscopy: quantification by calibration
- GC-FID: quatification
3. Other side productsⅣ. Market development through supply chain enlargement of artemisinin
More than 150 natural products
A. annua
HPLC-UV-MS HPLC-UV
-Extinction coefficients (흡광계수 )
4. Extraction and purification 2004 onwards Ⅳ. Market development through supply chain enlargement of artemisinin
Analytical method (TLC-FID)
- Accurate- Quickly- Results with and auto-mated evaluation
Purification method- Chromatography → crystal-lization . Waxes co-precipitating . Plugging during filtrations . With major related sub-stance (dehydro-artemisinin)
Synthetic production- Semi-synthesis (artemisinic acid → artemisinnin)- Cost non-competitive